Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial

BACKGROUND: Coagulation activation and venous thromboembolism (VTE) are hallmarks of malignant disease and represent a major cause of morbidity and mortality in cancer. Coagulation inhibition with low-molecular-weight heparin (LMWH) may improve survival specifically in small-cell lung cancer (SCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ek, L, Gezelius, E, Bergman, B, Bendahl, P O, Anderson, H, Sundberg, J, Wallberg, M, Falkmer, U, Verma, S, Belting, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834130/
https://www.ncbi.nlm.nih.gov/pubmed/29106448
http://dx.doi.org/10.1093/annonc/mdx716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834130/
https://www.ncbi.nlm.nih.gov/pubmed/29106448
http://dx.doi.org/10.1093/annonc/mdx716

Ejemplares similares